Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Hims & Hers Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the lawsuit is from April 29, 2025, to June 23, 2025, and the lead plaintiff deadline is August 25, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2][5] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - In 2019, Rosen Law Firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3] Group 3: Case Allegations - The lawsuit alleges that Hims & Hers Health, Inc. made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy [4] - Specific claims include that Hims failed to disclose the nature of its collaboration with Novo and the implications for its subscribers' access to Wegovy and compounded semaglutide products [4] - The lawsuit asserts that when the true details were revealed, investors suffered damages as a result of these misleading statements [4]

Core Insights - Iovance Biotherapeutics reported a wider loss of $0.33 per share for Q2 2025, exceeding the Zacks Consensus Estimate of a loss of $0.29, while revenues increased by 93% year-over-year to $60 million, falling short of the expected $66.4 million [1][10] Financial Performance - The company generated $54.1 million from Amtagvi sales, up from $43.6 million in the previous quarter, surpassing both the Zacks Consensus Estimate of $53.3 million and the internal estimate of $53.5 million, with over 100 patients infused during the quarter [3] - Proleukin contributed $5.9 million in sales, a decline of 68% year-over-year, missing the Zacks Consensus Estimate and internal estimates of $18 million [4] Operating Costs - Research and development expenses rose to $79.4 million, a 28% increase from the previous year, primarily due to higher employee and clinical costs [5] - Selling, general, and administrative expenses decreased by 5% to $37.7 million, attributed to lower stock compensation expenses [5] Guidance and Strategic Initiatives - Iovance maintained its product revenue guidance for the year, projecting revenues between $250 million and $300 million, driven by strong demand for its marketed products [6] - The company announced a strategic restructuring plan aimed at saving over $100 million annually, which includes laying off nearly 19% of its workforce [7] Cash Management and Future Outlook - Iovance expects net cash burn to be less than $245 million over the next four quarters, with cost savings extending the cash runway into Q4 2026 [8] - The company anticipates significant growth in total product revenues for 2026 and beyond, with gross margins expected to improve through optimization of manufacturing capacity [8] Regulatory Developments - Iovance has withdrawn its regulatory filing for Amtagvi in the European Union due to data alignment issues with the EMA, while applications in the UK, Canada, and Australia are under review [11][12] - The company is evaluating Amtagvi in combination with Merck's Keytruda in a phase III study for advanced melanoma, which will also serve as a confirmatory study for full approval [16] Stock Performance - Shares of Iovance fell nearly 29% in after-market trading following the news of the EU filing withdrawal, contributing to a year-to-date decline of 64% compared to a 1% decline in the industry [12][14]

ETFs that follow the tech-saturated Nasdaq 100 surged to record-time highs on Thursday, despite the U.S. imposing its broadest tariff increase in nearly 100 years.QQQ is hovering around its all-time highs. Track live prices here.Leading the pack were:Invesco QQQ Trust QQQInvesco NASDAQ 100 ETF QQQMDirexion NASDAQ 100 Equal Weighted Index Shares QQQEThese ETFs have bucked rising geopolitical tensions and a surge in trade-related uncertainty, reflecting investor confidence in the stability of big-cap U.S. tec ...

NuScale remains a speculative, long-term-only investment prospect -- and yesterday's earnings didn't matter at all.Nuclear power start-up stock NuScale Power (SMR -11.21%) disappointed investors with its second-quarter financial report last night, and the stock is down 8.2% through 12:15 p.m. Friday.Heading into the report, analysts forecast NuScale would generate about $11.7 million in revenue but remain unprofitable. Actual revenue was only $8.1 million, however, and NuScale lost $0.13 per share. NuScale ...

Group 1 - The NFL's part-ownership of Disney's ESPN highlights the league's significance in supporting the struggling traditional television industry [2] - Geico and Progressive are recognized for their contributions to maintaining the financial viability and entertainment value of linear television through their advertising efforts [2][3] - The advertising strategies of Geico and Progressive, featuring memorable characters and campaigns, play a crucial role in sustaining the traditional television model [3]

Core Viewpoint - Growth investors seek stocks with above-average financial growth, but identifying such stocks can be challenging due to associated risks and volatility [1] Group 1: Company Overview - Barrett Business Services (BBSI) is currently recommended as a cutting-edge growth stock by the Zacks Growth Style Score system, which evaluates a company's real growth prospects beyond traditional metrics [2] - Barrett has a favorable Growth Score and a top Zacks Rank, indicating strong potential for growth investors [10] Group 2: Earnings Growth - The historical EPS growth rate for Barrett is 13.1%, with projected EPS growth of 8.1% this year, significantly outperforming the industry average of 5.5% [5] Group 3: Asset Utilization - Barrett's asset utilization ratio (sales-to-total-assets ratio) is 1.6, indicating that the company generates $1.6 in sales for every dollar in assets, surpassing the industry average of 1.32 [6] Group 4: Sales Growth - The company's sales are expected to grow by 9.5% this year, compared to the industry average of 1.3%, highlighting Barrett's strong sales growth potential [7] Group 5: Earnings Estimate Revisions - The current-year earnings estimates for Barrett have been revised upward, with the Zacks Consensus Estimate increasing by 1.7% over the past month, indicating positive momentum [8]

Core Viewpoint - The article highlights Fabrinet as a promising growth stock, supported by its strong earnings growth, cash flow growth, and positive earnings estimate revisions, making it a suitable choice for growth investors [2][10]. Group 1: Earnings Growth - Fabrinet has a historical EPS growth rate of 25.6%, with projected EPS growth of 17.5% for the current year, surpassing the industry average of 15.9% [5][4]. Group 2: Cash Flow Growth - The year-over-year cash flow growth for Fabrinet is 14.4%, significantly higher than the industry average of -14% [6]. - The company's annualized cash flow growth rate over the past 3-5 years is 17.1%, compared to the industry average of 5.1% [7]. Group 3: Earnings Estimate Revisions - The current-year earnings estimates for Fabrinet have been revised upward, with the Zacks Consensus Estimate increasing by 3.6% over the past month [8]. - This positive trend in earnings estimate revisions contributes to Fabrinet's Zacks Rank of 2 (Buy) [10]. Group 4: Overall Positioning - Fabrinet's combination of a Growth Score of B and a Zacks Rank of 2 positions it well for potential outperformance in the market, making it an attractive option for growth investors [10].

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying strong candidates can be challenging due to inherent risks and volatility [1] Group 1: Company Overview - Idexx Laboratories (IDXX) is highlighted as a recommended growth stock with a favorable Growth Score and a top Zacks Rank [2] - The company operates in the animal diagnostic and health care sector, which is currently experiencing promising growth opportunities [3] Group 2: Earnings Growth - Idexx has a historical EPS growth rate of 12.5%, with projected EPS growth of 16.6% this year, surpassing the industry average of 12.4% [5] - Earnings growth is a critical factor for growth investors, as double-digit growth is often seen as indicative of strong future prospects [4] Group 3: Cash Flow Growth - The year-over-year cash flow growth for Idexx is currently at 6%, significantly higher than the industry average of -2.6% [6] - Over the past 3-5 years, Idexx has maintained an annualized cash flow growth rate of 14.6%, compared to the industry average of 6.3% [7] Group 4: Earnings Estimate Revisions - The current-year earnings estimates for Idexx have been revised upward, with the Zacks Consensus Estimate increasing by 3.8% over the past month [9] - Positive trends in earnings estimate revisions are correlated with near-term stock price movements, indicating strong potential for Idexx [8] Group 5: Investment Positioning - Idexx has achieved a Growth Score of A and a Zacks Rank of 2, positioning it well for potential outperformance in the growth stock category [10][11]

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying the right ones can be challenging due to inherent volatility and risks [1] Group 1: Company Overview - SunOpta (STKL) is currently highlighted as a recommended growth stock by the Zacks Growth Style Score system, which evaluates a company's genuine growth potential [2] - The company has a favorable Growth Score and a top Zacks Rank, indicating strong investment potential [2] Group 2: Earnings Growth - Historical EPS growth for SunOpta stands at 84%, with projected EPS growth of 63.6% for the current year, significantly surpassing the industry average of 6.7% [5] - Earnings growth is a critical factor for investors, with double-digit growth being particularly desirable [4] Group 3: Cash Flow Growth - SunOpta's year-over-year cash flow growth is 22.3%, well above the industry average of 4.3%, highlighting its strong financial health [6] - The company's annualized cash flow growth rate over the past 3-5 years is 46.1%, compared to the industry average of 4.3%, indicating robust historical performance [7] Group 4: Earnings Estimate Revisions - There have been upward revisions in current-year earnings estimates for SunOpta, with the Zacks Consensus Estimate increasing by 2.9% over the past month [9] - Positive trends in earnings estimate revisions are correlated with near-term stock price movements, reinforcing the stock's potential [8] Group 5: Investment Positioning - SunOpta has achieved a Zacks Rank of 2 (Buy) and a Growth Score of A, positioning it favorably for outperformance in the growth stock category [10][11]

 Vancouver, B.C. – TheNewswire - August 8, 2025 – Aether Global Innovations Corp. (CSE: AETH) (OTC: AETHF) (Frankfurt: 4XA) (WKN# A2N8RH), a leader in drone management and automation, announces, further to its news release of May 16, 2025, that effective on Tuesday, August 12, 2025, the Company will consolidate its common shares (the “Common Shares”) on the basis of one (1) post consolidated Common Share to every ten (10) pre-consolidated Common Shares (the “Consolidation”). The name of the Company and tra ...